116129-88-5

Usage

Uses

Used in Pharmaceutical Industry:
(R)-2-Benzyl-succinic acid 1-benzyl ester 4-tert-butyl ester is used as a building block for the synthesis of complex pharmaceutical compounds. Its unique structure allows for the creation of new drugs with potential therapeutic applications.
Used in Materials Science:
In the field of materials science, (R)-2-benzyl-succinic acid 1-benzyl ester 4-tert-butyl ester is used as a component in the development of novel materials with specific properties. Its versatile reactivity enables the creation of materials with tailored characteristics for various applications.
Used in Biochemistry:
(R)-2-Benzyl-succinic acid 1-benzyl ester 4-tert-butyl ester is utilized as a key intermediate in the synthesis of bioactive molecules. Its unique structure can be exploited to design and develop new biochemical compounds with potential applications in research and therapeutics.
Used in Organic Synthesis:
This chemical compound is also used as an intermediate in organic synthesis, where it can be further modified or reacted with other molecules to create a wide range of complex chemical structures for various applications.

Upstream product

• 150544-79-9 (4S)-3-<(2R)-2-<(tert-butyloxycarbonyl)methyl>-3-phenylpropionyl>-4-benzyloxazolidin-2-one 
• 100-51-6 benzyl alcohol 
• 116129-79-4 (4S)-3-<(2R)-2-<(tert-butyloxycarbonyl)methyl>-3-phenylpropionyl>-4-(2-propyl)oxazolidin-2-one 
• 5292-43-3 bromoacetic acid tert-butyl ester 
• 645-45-4 hydrocinnamic acid chloride 
• 136159-65-4 (S)-4-benzyl-3-(3-phenylpropanoyl)oxazolidin-2-one 
• 95798-31-5 (4S)-3-(3-phenylpropionyl)-4-(2-propyl)oxazolidin-2-one 

Downstream Products

• 116129-80-7 (3R)-3-Benzyloxycarbonyl-3-phenylmethylpropionic acid 
• 122225-33-6 (2R)-3-tert-Butyloxycarbonyl-2-phenylmethylpropionic Acid 
• 122225-67-6 benzyl (2R)-2-benzyl-3-<(chloromethyl)carbonyl>propionate 
• 122225-29-0 Benzyl-(2R)-2 benzyl 3-(N-morpholino-carbamoyl)-propionate 
• 122225-70-1 Benzyl (2R)-2-Benzyl-5-tert-butylmercapto-4-oxopentanoate 
• 122225-75-6 benzyl (2R)-2-benzyl-5-morpholin-4-yl-4-oxopentanoate 
• 140926-08-5 (2S,3R,4S)-2-<-3-(4-thiazolyl)-L-alanyl>amino>-1-cyclohexyl-3,4-dihydroxy-6-methylheptane 
• 135683-92-0 N--(2S,3R,4S)-1-cyclohexyl-3,4-dihydroxy-6(2-pyridyl)-hexane-2-amide acetate 
• 135650-85-0 (2S,3R,4S)-N-piperidyl>carbonyl>propionyl>N^im-2-(2,4-dinitrophenyl)-L-histidinyl>-1-cyclohexyl-3,4-dihydroxy-6-(2-pyridyl)hexan-2-amine 
• 135631-93-5 (2S,3R,4S)-N-piperidyl>carbonyl>propionyl>-L-histidinyl>-1-cyclohexyl-3,4-dihydroxy-6-(2-pyridyl)hexan-2-amine 
• 135632-14-3 (1-{(R)-3-[(R)-1-((1S,2R,3S)-1-Cyclohexylmethyl-2,3-dihydroxy-5-pyridin-2-yl-pentylcarbamoyl)-2-methylsulfanyl-ethylcarbamoyl]-4-phenyl-butyryl}-piperidin-4-yl)-carbamic acid tert-butyl ester 
• 135632-41-6 (1-{(R)-3-[(S)-1-((1S,2R,3S)-1-Cyclohexylmethyl-2,3-dihydroxy-5-pyridin-2-yl-pentylcarbamoyl)-butylcarbamoyl]-4-phenyl-butyryl}-piperidin-4-yl)-carbamic acid tert-butyl ester 
• 135632-30-3 benzyl (2R)-3-<1-<<4-<(tert-butyloxycarbonyl)amino>piperidinyl>carbonyl>-2-benzyl>propionate 
• 135632-29-0 (2R)-3-<1-<<4-<(tert-butyloxycarbonyl)amino>piperidinyl>carbonyl>-2-benzyl>propionic acid 

Relevant academic research and scientific papers

Renin inhibitors containing a pyridyl amino diol derived C-terminus

Based on the concept of transition-state analogs, a series of nonpeptide renin inhibitors with the new (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy- 6-(2-pyridyl)hexane moiety at the C-terminal functionality were synthesized and evaluated for inhibition

HETEROCYCLIC PEPTIDE RENIN INHIBITORS

A renin inhibiting compound of the formula STR1 wherein X is N, O or CH; R 1 is absent or a functional group; A and L are independently selected from absent, C=O, SO 2 and CH 2 ; D is C=O, SO. sub.2 or CH 2 ; Y is N or CH; R 2 is hydrogen, loweralkyl or substituted alkyl; Z is a functional group; R 3 is loweralkyl or substituted alkyl; n is 0 or 1; and T is a mimic of the Leu-Val cleavage site of angiotensinogen; or a pharmaceutically acceptable salt, ester or prodrug thereof.

Glaucoma treatment

A method and a composition for treating or reducing and/or controlling intraocular pressure comprising administering an effective amount of a renin inhibiting compound of the formula: STR1 where A is a substituent; W is CO or CHOH and U is CH2 or NR2 wherein R2 is hydrogen or loweralkyl; with the proviso that when W is CHOH then U is Ch2 ; R1 is loweralkyl, cycloalkyl methyl, benzyl, (alpha, alpha)-dimethylbenzyl, 4-hydroxybenzyl, 4-methoxybenzyl, halobenzyl, (1-naphthyl)methyl, (2-naphthyl)methyl, 1-bezyloxyethyl, phenethyl, phenoxy, thiophenoxy or anilino; R3 is loweralkyl, loweralkenyl, ((alkoxy)alkoxy)loweralkyl, (thioalkoxy)alkyl, benzyl or heterocyclic ring substituted methyl; and R4 is substituted hydroxyalkyamino.

PEPTIDYL AMINODIOL RENIN INHIBITORS

A renin inhibiting compound having an aminodiol functional group is useful for treating hypertension, congestive heart failure and glaucoma and inhibits retroviral protease.

Peptidyl difluorodiol renin inhibitors

A renin inhibiting compound of the formula: wherein A is a functional group; W is (1)-C(O)-,(2)-CH(OH)-or(3)-N(R?)-wherein R? is hydrogen or loweralkyl; U is (1)-C(O)-,(2)-CH?-or(3)-N(R?)-wherein R? is hydrogen or lower alkyl, with the proviso that when W is-CH(OH)-then U is-CH?-and with the proviso that U is-C(O)-or-CH?-when W is-N(R?)-; V is (1)-CH-,(2)-C(OH)-or(3)-C(halogen)-with the proviso that v is-CH--when U is-N(R?)-; Q is-CH(R?)-or-C(=CHR1a)-wherein R? is (1) loweralkyl,(2) cycloalkylalkyl,(3) arylalkyl,(4) (heterocyclic) alkyl,(5) 1-benzyloxyethyl,(6) phenoxy,(7) thiophenoxy or(8) anilino, provided that B is-CH?-or-CH(OH)-or A is hydrogen when R? is phenoxy, thiophenoxy or anilino and R1a is aryl or heterocyclic; R? is a functional group; R? is (1) loweralkyl,(2) cycloalkylmethyl or(3) benzyl; R? is-CH(OH)-or-C(O)-; R? is-CH(OH)-or-C(O)-; and Z is (1) lower alkyl,(2) aryl,(3) arylalkyl,(4) cycloalkyl,(5) cycloalkylalkyl,(6) heterocyclic or(7) (heterocyclic)alkyl; or a pharmaceutically acceptable salt, ester or prodrug thereof.

Glaucoma treatment

A method and a composition for treating or reducing and/or controlling intraocular pressure comprising administering an effective amount of a renin inhibiting compound of the formula: STR1 wherein A is a substituent; W is CO or CHOH and U is CH2/sub

Angiotensinogen analogs

The invention relates to renin inhibiting compounds of the formula STR1 wherein A is hydrogen; loweralkyl; arylalkyl; OR10 or SR10 wherein R10 is hydrogen, loweralkyl or aminoalkyl; NR11 R12 wherein R11 and R12 are independently selected from hydrogen, loweralkyl, aminoalkyl, cyanoalkyl and hydroxyalkyl; STR2 wherein B is NH, alkylamino, S, O, CH2 or CHOH and R13 is loweralkyl, cycloalkyl, aryl, arylalkyl, alkoxy, alkenyloxy, hydroxyalkoxy, dihydroxyalkoxy, arylalkoxy, arylalkoxyalkyl, amino, alkylamino, dialkylamino, (hydroxyalkyl)(alkyl)amino, (dihydroxyalkyl)(alkyl)amino, aminoalkyl, alkoxycarbonylalkyl, carboxyalkyl, N-protected aminoalkyl, alkylaminoalkyl, (N-protected)(alkyl)aminoalkyl, dialkylaminoalkyl, (heterocyclic) alkyl or a substituted or unsubstituted heterocyclic; W is CO or CHOH and U is CH2 or NR2 with the proviso that when W is CHOH then U is CH2 ; R1 is loweralkyl, cycloaklylmethyl, benzyl, α,α-dimethylbenzyl, 4-methoxybenzyl, halobenzyl, (1-naphthyl)methyl, (2-naphthyl)methyl, (4-imidazoyl)-methyl, phenethyl, phenoxy, thiophenoxy or anilino; provided if R1 is phenoxy, thiophenoxy or anilino, B is CH2 or CHOH or A is hydrogen, R3 is loweralkyl, vinylloweralkyl, benzyl or heterocyclic ring substituted methyl, R5 is loweralkyl, cycloalkylmethyl or benzyl; R2 and R4 are independently selected from hydrogen and loweralkyl; R6 is CHOH or CO; R7 is CH2, CF2 or CF with the proviso that when R6 is CO, R7 is CF2 ; R8 is CH2, CHR14 wherein R14 is lower-alkyl, cycloalkyl, cycloalkylalkyl, aryl or arylalkyl, or R7 and R8 taken together can be STR3 with the proviso that when R7 is CF2, R8 is CH2 ; E is O, S, SO, SO2, NR15 wherein R15 is hydrogen or loweralkyl or NR16 CO wherein R16 is hydrogen or loweralkyl; R9 is loweralkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl or an N-protected group, or E and R9 taken together can be N3, with the proviso that when E is NH, R9 is an N-protecting group; and pharmaceutically acceptable salts thereof.

Renin-inhibiting functionalized peptidyl aminodiols and - triols

A renin inhibiting compound of the formula: or a pharmaceutically acceptable salt, ester or prodrug thereof.

Renin-inhibiting peptidyl heterocycles

A renin inhibiting compound of the formula:*(formula 01)* wherein A is a substituent; W is C=O, CHOH or NR2 wherein R2 is hydrogen or loweralkyl; U is C=O, CH2 or NR2 wherein R2 is hydrogen or loweralkyl, with the proviso that when W is CHOH then U is CH2 and with the proviso that U is C=O or CH2 when W is NR2; V is CH, C(OH) or C(halogen) with the proviso that V is CH when U is NR2; R1 is loweralkyl, cycloalkylalkyl, benzyl, (alpha, alpha)-dimethylbenzyl, 4-methoxybenzyl, halobenzyl, 4-hydroxybenzyl, (1-naphthyl)methyl, (2-naphthyl)methyl, (unsubstituted heterocyclic)methyl, (substituted heterocyclic)methyl, phenethyl, 1-benzyloxyethyl, phenoxy, thiophenoxy or anilino, provided that B is CH2 or CHOH or A is hydrogen when R1 is phenoxy, thiophenoxy or anilino; R3 is loweralkyl, loweralkenyl, ((alkoxy)alkoxy)alkyl, carboxyalkyl, (thioalkoxy)alkyl, azidoalkyl, aminoalkyl, (alkyl)aminoalkyl, dialkylaminoalkyl,(alkoxy)(alkyl)aminoalkyl, (alkoxy)aminoalkyl, benzyl or heterocyclic ring substituted methyl; R4 is loweralkyl, cycloalkylmethyl or benzyl; R5 is OH or NH2; and Z is a substituent. Also disclosed are compositions for and a method of treating hypertension, methods of making the renin inhibiting compounds and intermediates useful in making the renin inhibiting compounds.

Renin inhibitors. Dipeptide analogues of angiotensinogen utilizing a structurally modified phenylalanine residue to impart proteolytic stability

A series of renin inhibitors have been prepared and evaluated for their susceptibility to cleavage by the serine protease chymotrypsin. The compounds were designed by consideration of the structural requirements in the active-site region of renin and chymotrypsin. By systematic alteration of the P3 phenylalanine residue, compounds with varying degrees of renin inhibitory potency and chymotrypsin susceptibility were obtained. Selected analogues from this group were examined in vivo for both their hypotensive effects and metabolic patterns.